Kala Pharmctls (NASDAQ:KALA) major shareholder Associates L.L.C. Cdk acquired 215,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was acquired at an average cost of $15.00 per share, with a total value of $3,225,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Kala Pharmctls (KALA) traded down 1.66% during midday trading on Friday, reaching $21.36. The company’s stock had a trading volume of 58,614 shares. The stock’s market capitalization is $497.32 million. The firm has a 50-day moving average price of $18.32 and a 200 day moving average price of $18.32. Kala Pharmctls has a 52-week low of $16.38 and a 52-week high of $23.08.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/insider-buying-kala-pharmaceuticals-inc-kala-major-shareholder-buys-215000-shares-of-stock-updated-updated-updated.html.
A number of brokerages recently issued reports on KALA. Oppenheimer Holdings, Inc. began coverage on Kala Pharmctls in a report on Tuesday. They issued an “outperform” rating and a $46.00 price objective for the company. Bank of America Corporation began coverage on Kala Pharmctls in a report on Monday. They issued a “buy” rating and a $33.00 price objective for the company. Wells Fargo & Company began coverage on Kala Pharmctls in a report on Monday. They issued an “outperform” rating and a $24.00 price objective for the company. Wedbush started coverage on Kala Pharmctls in a report on Monday. They issued an “outperform” rating and a $46.00 price objective for the company. Finally, J P Morgan Chase & Co started coverage on Kala Pharmctls in a research report on Monday. They issued an “overweight” rating and a $35.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Kala Pharmctls currently has a consensus rating of “Buy” and an average target price of $36.80.
Kala Pharmctls Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmctls Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmctls and related companies with MarketBeat.com's FREE daily email newsletter.